LCM
TEVA icon

Lionhunter Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Lionhunter Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$610K Buy
+18,000
New +$600K 0.28% 74

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Lionhunter Capital Management's TEVA Position: Q2 2026 in Review

Lionhunter Capital Management opened a new position in Teva Pharmaceuticals (TEVA) in Q2 2026: 18,000 shares worth $610K. The stake represents 0.28% of the portfolio and ranks #74 among its holdings.

639 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Lionhunter Capital Management held 18,000 shares of Teva Pharmaceuticals worth $610K as of Q2 2026.
  • Teva Pharmaceuticals was a new Lionhunter Capital Management position in Q2 2026.
  • Teva Pharmaceuticals made up 0.28% of Lionhunter Capital Management's portfolio in Q2 2026, its #74 holding.
  • 639 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Lionhunter Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.